摘要
目的研究力栓饮对急性冠脉综合征(acute coronary syndrome,ACS)患者经皮冠状动脉介入术(percutaneous coronary intervention,PCI)治疗后血清内皮素-1(ET-1)及纤溶酶原激活物抑制因子1(PAI-1)的影响,观察力栓饮在急性冠脉综合征患者PCI术后的作用及机制探讨。方法选取2020年1月—2021年1月山西省中医院心血管一科收治的拟行PCI治疗的80例ACS患者,按随机对照原则分为两组,对照组和治疗组,每组40例。对照组PCI治疗后常规给予抗凝、抗血小板聚集及降脂等治疗,治疗组在此基础上联合力栓饮治疗。治疗结束后,观察两组患者PCI术前后指标及主要心脏不良事件。结果治疗组患者治疗后内皮素-1(ET-1)含量为(134.98±45.82)pg/mL、纤溶酶原激活物抑制因子1(PAI-1)含量为(90.63±19.91)ng/mL,显著优于对照组患者,差异有统计学意义(t=2.370、2.247,P<0.05)。治疗组患者的不良心血管事件发生率为7.5%,显著低于对照组患者,差异有统计学意义(χ^(2)=9.038,P=0.003)。结论急性冠脉综合证患者PCI术后基础治疗加用力栓饮可降低ET-1、PAI-1含量,延缓动脉粥样硬化,减少PCI术后并发症。
Objective To study the effect of Lishuan Decoction on serum endothelin-1(ET-1)and plasminogen activator inhibitor 1(PAI-1)in patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).To observe the effect and mechanism of Lishuan Decoction in patients with acute coronary syndrome after PCI.Methods A total of 80 patients with ACS who were admitted to the Department of Cardiology,Shanxi Provincial Hospital of Traditional Chinese Medicine from January 2020 to January 2021 and planned to undergo PCI were selected.According to the principle of random control,they were divided into two groups,the control group and the treatment group,with 40 cases in each group.The control group was given routine anticoagulation,antiplatelet aggregation and lipid-lowering treatment after PCI,and the treatment group was given Lishuan Decoction on this basis.After the treatment,the indicators before and after PCI and the main adverse cardiac events in the two groups were observed.Results After treatment,the content of endothelin-1(ET-1)in the treatment group was(134.98±45.82)pg/mL,and the content of plasminogen activator inhibitor 1(PAI-1)was(90.63±19.91)ng/mL.It was significantly better than the control group,and the difference was statistically significant(t=2.370,2.247,P<0.05).The incidence of adverse cardiovascular events in the treatment group was 7.5%,which was significantly lower than that in the control group,the difference was statistically significant(χ^(2)=9.038,P=0.003).Conclusion The basic treatment of acute coronary syndrome patients after PCI plus Lishuan Decoction can reduce the content of ET-1 and PAI-1,delay atherosclerosis,and reduce the complications after PCI.
作者
武丽萍
高健元
WU Liping;GAO Jianyuan(Department of Cardiology,Shanxi Provincial Hospital of Traditional Chinese Medicine,Taiyuan,shanxi Province,030012 China)
出处
《系统医学》
2022年第9期38-41,46,共5页
Systems Medicine
基金
山西省中医药研究院院级课题(201809)。
